BrainsWay Ltd. (TLV:BWAY)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 977.55M |
| Revenue (ttm) | 155.27M |
| Net Income (ttm) | 18.01M |
| Shares Out | 38.01M |
| EPS (ttm) | 0.37 |
| PE Ratio | 69.86 |
| Forward PE | 42.05 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,937 |
| Average Volume | 54,420 |
| Open | 2,511.00 |
| Previous Close | 2,529.00 |
| Day's Range | 2,511.00 - 2,600.00 |
| 52-Week Range | 1,444.00 - 2,795.00 |
| Beta | 0.25 |
| RSI | 50.56 |
| Earnings Date | Nov 12, 2025 |
About BrainsWay
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson’s diseases. The company serves do... [Read more]
News
Do Options Traders Know Something About Brainsway Stock We Don't?
Investors need to pay close attention to Brainsway stock based on the movements in the options market lately.
BWAY Shares Gain on FDA Nod for Accelerated Deep TMS Depression Care
BrainsWay shares surge after the FDA cleared its accelerated Deep TMS protocol, offering faster depression treatment with strong clinical results.
FDA Clearance Boosts BrainsWay (BWAY) Shares
FDA Clearance Boosts BrainsWay (BWAY) Shares
BrainsWay rises as FDA clears accelerated Deep TMS protocol
BrainsWay (BWAY) Gains FDA Approval for Enhanced Depression Treatment Protocol
BrainsWay (BWAY) Gains FDA Approval for Enhanced Depression Treatment Protocol
BrainsWay Targets Expansion of its Total Addressable Market through a Strategic Investment in Neuromodulation Systems Developer, Neurolief Ltd.
This investment marks BrainsWay's entrance into the market for mental health therapies that can be administered outside of a clinic, including at home
BrainsWay Acquires Minority-Stake in Axis Integrated Mental Health
The Investment is part of BrainsWay's ongoing strategy to acquire minority positions in leading U.S. mental health providers to help them raise awareness for and expand access to transformative care T...
BrainsWay Ltd. (BWAY) Q2 2025 Earnings Call Transcript
BrainsWay Ltd. (NASDAQ:BWAY) Q2 2025 Earnings Conference Call August 13, 2025 8:30 AM ET Company Participants Hadar Levy - Chief Executive Officer Ido Marom - Chief Financial Officer Conference Call ...
BrainsWay Reports Second Quarter 2025 Financial Results and Operational Highlights
Achieved record quarterly revenue of $12.6 million in Q2 2025, an increase of 26% compared to Q2 2024 Operating profit totaled $0.6 million and Adjusted EBITDA rose to $1.5 million, Raised full-year 2...
BrainsWay Q2 2025 Earnings Preview
BrainsWay Reports Positive Results from Multicenter Randomized Study of Accelerated Deep TMS for Major Depressive Disorder (MDD)
Improvement in depression scores, response and remission were all found to be comparable with standard Deep TMS in non-inferiority trial Improvement in depression scores, response and remission were a...
BrainsWay Announces Gold Sponsorship at the 2025 Clinical TMS Society Annual Meeting in San Diego
BURLINGTON, Mass. and JERUSALEM, June 10, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd.
BrainsWay Announces $5 Million Minority-Stake Investment in Stella MSO, LLC
BrainsWay is actively evaluating similar investments in other leading U.S. mental health providers to raise awareness and expand access to transformative care BrainsWay is actively evaluating similar ...
BrainsWay Ltd. (BWAY) Q1 2025 Earnings Call Transcript
BrainsWay Ltd. (NASDAQ:BWAY) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Brian Ritchie – LifeSci Advisors LLC Hadar Levy – Chief Executive Officer Ido Marom – Chief ...
BrainsWay GAAP EPS of $0.02 in-line, revenue of $11.54M beats by $0.09M
BrainsWay Reports First Quarter 2025 Financial Results and Operational Highlights
Achieved r ecord quarterly s ales of $11. 5 million in Q 1 202 5 , an increase of 27% compared to Q 1 202 4
BrainsWay Q1 2025 Earnings Preview
BrainsWay: Strong Growth Prospects Matter Little To The Market
BrainsWay Ltd. (BWAY) Q4 2024 Earnings Call Transcript
BrainsWay Ltd. (NASDAQ:BWAY) Q4 2024 Earnings Conference Call March 11, 2025 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors Hadar Levy - Chief Executive Officer ...
BrainsWay GAAP EPS of $0.04 beats by $0.02, revenue of $11.41M beats by $0.52M
BrainsWay reports Q4 GAAP EPS of $0.04, revenue up 26.4% Y/Y, and strong 2025 guidance. Growth in Deep TMS™ adoption driving profitability.
BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
Achieved r ecord quarterly s ales of $11.4 million in Q4 2024 , an increase of 27% compared with Q4 2023
Earnings Scheduled For March 11, 2025
Companies Reporting Before The Bell • Exagen (NASDAQ: XGN) is projected to report quarterly loss at $0.24 per share on revenue of $13.85 million. • Core Molding Technologies (AMEX: CMT) is expected ...
BrainsWay Q4 2024 Earnings Preview
BrainsWay Reports Positive Independent Pilot Data on Accelerated Deep TMS Treatment of Alcohol Use Disorder
BURLINGTON, Mass. and JERUSALEM, Dec. 12, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain ...
BrainsWay Reports Promising Feasibility Data Showing Pain Reduction with Deep TMS Therapy
BURLINGTON, Mass. and JERUSALEM, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd.